[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiomyopathies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiomyopathies":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,50,0,25,[9,53,87,112,141,167,200,234,266,298,325,351,376,398,426,452,478,514,542,572,601,632,663,691,723],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100559420","phase-3-acoramidis-transthyretin-amyloidosis-prevention-trial-in-the-young-act-early-study-in-asymptomatic-carriers-of-a-pathogenic-ttr-variant-100559420",false,"NCT06563895","Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant","A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)","Key Inclusion Criteria:\n\n* Male or female ≥ 18 to ≤ 75 years of age inclusive.\n* Participants must have an established genotype (hetero- or homozygosity) through a medically-indicated genetic test of a TTR gene variant that is known to be pathogenic or likely pathogenic (eg, V30M\u002Fp.V50M, V122I\u002Fp.V142I, T60A\u002Fp.T80A, or all other pathogenic TTR variants).\n* Participant's age is within 10 years younger than or older than PADO.\n\nKey Exclusion Criteria:\n\n* Evidence of ATTR-CM or ATTR-PN.\n* Current or past (within last 1 to 12 months, depending on specific agent) treatment with other TTR modifying therapies.\n* Contraindication to or inability to undergo cardiac magnetic resonance testing.\n* Major organ dysfunction, including: kidney disease, liver disease, heart disease (including cardiomyopathy), neuropathy\n* Other diseases or conditions such has cancer within 5 years, untreated hyperthyroidism or hypothyroidism, type 1 diabetes, active hepatitis B or C, HIV.\n* Major surgery within the past 3 months or planned during the next 12 months.\n* Known hypersensitivity to acoramidis.","ALL","18 Years","75 Years",{"count":21,"type":22},587,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid that may no longer be sufficiently cleared by the body. This type of ATTR is known as wild-type ATTR (ATTRwt). The other way occurs when a person inherits a defective TTR gene that causes the TTR protein to spontaneously fall apart. This form of the disease is known as variant ATTR (ATTRv) and can be detected in adults by a genetic test of their TTR gene before they age.\n\nAmyloid build-up in the heart causes the heart wall to become thick and stiff and can result in heart failure and even death. Accumulation of TTR amyloid in the heart is known as transthyretin amyloid cardiomyopathy or ATTR-CM. Amyloid can also deposit in the nerve tissues leading to nerve problems. Accumulation of TTR in the nerves is known as transthyretin amyloid polyneuropathy or ATTR-PN.\n\nAcoramidis is an experimental drug designed to bind tightly to TTR in the blood and stabilize its structure, so it does not form the harmful amyloid plaques that can cause damage to organs.\n\nThis study is intended to determine if treatment with acoramidis in participants with ATTRv who have not yet developed any symptoms of disease can prevent or delay the development of ATTR-CM or ATTR-PN disease. If adults with an inherited defective TTR gene are treated early before any of the symptoms of disease have developed, it may be possible to delay the onset or prevent the disease entirely.",[28,29,30,31,32,33],"Amyloidosis","Amyloid Cardiomyopathy","Transthyretin Amyloidosis","Cardiomyopathies","Heart Diseases","Polyneuropathies",[28,35,36,37,38,39],"ATTR-CM","ATTR-PN","Transthyretin","Amyloid","TTR","RECRUITING","2026-06-25",{"date":43,"type":44},"2026-06-29","ACTUAL",{"date":46,"type":44},"2025-05-12",{"date":48,"type":22},"2032-12",{"name":50,"class":51},"Eidos Therapeutics, a BridgeBio company","INDUSTRY",103,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100242269","pediatric-cardiomyopathy-mutation-analysis-100242269","NCT02432092","Pediatric Cardiomyopathy Mutation Analysis","Inclusion Criteria:\n\n* Subjects with cardiomyopathy\n* Family members of subjects with cardiomyopathy\n\nExclusion Criteria:\n\n* Subjects without cardiomyopathy\n* Family members of subjects without cardiomyopathy",{"count":60,"type":22},300,"OBSERVATIONAL","The goal of this protocol is to obtain information from individuals with cardiomyopathy and from their families in order to elucidate the molecular genetics of this disorder. This will provide the basis for future genetic counseling as well as contribute to elucidating the biology of normal and abnormal cardiac function.",[31,64,65,66,67,68],"Dilated Cardiomyopathy","Hypertrophic Cardiomyopathy","Restrictive Cardiomyopathy","Arrhythmogenic Right Ventricular Cardiomyopathy","Left Ventricular Non-compaction Cardiomyopathy",[70,71,32,72,73,74,75],"Cardiomegaly","Cardiovascular Diseases","Systolic dysfunction","Diastolic dysfunction","Ventricular hypertrophy","Heart failure","2026-06-17",{"date":78,"type":44},"2026-06-22",{"date":80,"type":4},"2014-04",{"date":82,"type":22},"2030-12-31",{"name":84,"class":85},"Indiana University","OTHER",1,{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":94,"minAge":18,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":86},"100641265","phase-1-human-mass-balance-study-of-chrs-1893-100641265","NCT07656779","Human Mass Balance Study of [¹⁴C]HRS-1893","Inclusion Criteria:\n\n1. Age range: 18 - 45 years old (inclusive of the boundaries, based on the date of signing the informed consent form). Healthy male.\n2. Body Mass Index (BMI) ranging from 19 to 26 kg\u002Fm2 (including the boundary values), with a weight of ≥ 50.0 kg.\n3. After comprehensive physical examinations (including vital signs, physical examinations, etc.) and laboratory tests (such as blood routine, blood biochemistry, coagulation function, urine routine, fecal routine + occult blood, thyroid function), as well as abdominal B-ultrasound and chest anteroposterior X-ray films, no clinically significant abnormalities were found (ALT, AST, total bilirubin, direct bilirubin, creatine kinase must be \\\u003C 1.5 times the upper limit of the normal reference value, glomerular filtration rate (eGFR) \\> 90 mL\u002F(min·1.73 m2)), or the researchers judged that there were minor abnormalities that did not affect the participants' enrollment (such as hemangioma, cyst, calcification focus, nodules, etc.). Among them, abdominal B-ultrasound and chest anteroposterior X-ray films can accept the abdominal B-ultrasound or abdominal CT that can be traced within 6 months before administration, and the results of chest anteroposterior X-ray films or chest CT.\n4. The 12-lead electrocardiogram shows no clinically significant abnormalities (among which QTc Fridericia (QTcF) must be \\\u003C 450 ms).\n5. Understand the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in person.\n\nExclusion Criteria:\n\n1. Systolic blood pressure (SBP) during the screening period or baseline period: SBP ≥ 140 mmHg or \\\u003C 90 mmHg; Diastolic blood pressure (DBP): DBP ≥ 90 mmHg or \\\u003C 60 mmHg, and the clinical doctor determines that it has clinical significance.\n2. During the screening period, any one of the following infectious disease screenings - hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, or human immunodeficiency virus antibody - showing any abnormal result and judged by the researcher to have clinical significance will be included.\n3. There is a history of syncope in the past.\n4. Those who have a history of allergies to drugs, foods, or the environment, or who are allergic to the test drug or any of its components.\n5. Within one month prior to taking the research drug, any prescription drugs, over-the-counter drugs, or herbal medicines were taken; those whose drug half-life was within five half-lives at the time of screening; and those who plan to take non-research trial drugs during the trial period.\n6. Select those who smoked an average of more than 5 cigarettes per day over the past 4 weeks; those who consumed an average of more than 15 grams of alcohol per day in a week (15 grams of alcohol is equivalent to 450 mL of beer or 150 mL of wine or 50 mL of low-alcohol liquor); or those whose alcohol breath test result was greater than 0 mg\u002F100 mL during the screening period; or those who refrained from smoking, drinking alcohol and consuming caffeinated foods or beverages during the screening period and the test period, and had special dietary requirements that they could not comply with the unified diet.\n7. Habitual constipation or diarrhea.\n8. Those with a history of drug use or substance abuse; or those who tested positive for drug abuse in the screening urine test during the selection process.\n9. Those who habitually consume grapefruit juice or excessive amounts of tea, coffee and\u002For caffeinated beverages, or those who are unable to quit during the trial period.\n10. Those who have a history of fainting during blood collection or blood transfusion, or who have difficulty in blood collection or cannot tolerate venipuncture for blood collection.\n11. Screen those who have participated in any clinical trials of drugs or medical devices within the past three months (the definition of participation in clinical trials is based on the participants receiving treatment with the trial drugs or medical devices).\n12. Those who received the vaccine within the previous 1 month or during the trial period or within 1 month after administration.\n13. Those who had experienced blood loss or blood donation of 400 mL within the past 3 months, or those who received blood transfusion within the past 1 month will be selected.\n14. Staff members of the research center or other individuals directly involved in the implementation of the plan.\n15. The researchers believe that there are other circumstances that make the participants unsuitable for this trial, such as those that might increase the risk of the trial, affect the participants' compliance with the protocol, or cause physical or psychological conditions that prevent them from completing the trial.",true,"MALE","45 Years",{"count":97,"type":22},6,[99],"PHASE1","HRS-1893-107 is a Phase 1, single-center, non-randomized, open-label, single-dose study designed to investigate the mass balance, metabolism, and pharmacokinetics of \\[14C\\]HRS-1893. The study aims to quantify the radioactive recovery rate, determine the primary excretion pathways, evaluate the whole blood-to-plasma radioactivity ratio, identify major metabolites, and characterize the pharmacokinetic (PK) profile of HRS-1893 and its metabolites. Safety and tolerability will be monitored throughout the trial.",[31],"NOT_YET_RECRUITING","2026-06-15",{"date":105,"type":44},"2026-06-18",{"date":107,"type":22},"2026-06",{"date":109,"type":22},"2026-07",{"name":111,"class":51},"Shandong Suncadia Medicine Co., Ltd.",{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":137,"leadSponsor":139,"locationsCount":86},"100640189","stereotactic-radioablation-as-first-line-therapy-for-scar-related-ventricular-tachycardia-100640189","NCT07618780","Stereotactic Radioablation as First-Line Therapy for Scar-Related Ventricular Tachycardia","Stereotactic Arrhythmia Radioablation as First-Line Treatment for Scar-Related Ventricular Tachycardia","START-VT","Inclusion Criteria:\n\n* Age 18 years or older and able to provide informed consent\n* Structural heart disease with myocardial fibrosis identified on pre-procedural imaging, including imaging evidence of regional myocardial akinesis\u002Fthinning or documented scar on echocardiography, cardiac CT, or cardiac MRI\n* Sustained monomorphic ventricular tachycardia (symptomatic or requiring ICD shocks for termination) within the previous 6 months\n\nExclusion Criteria:\n\n* Reversible causes of VT (e.g., active ischemia, drug-induced, electrolyte abnormalities)\n* Acute coronary syndrome within 30 days, coronary revascularization (\\\u003C90 days for bypass surgery, \\\u003C30 days for percutaneous coronary intervention)\n* Patients previously treated with high-dose radiotherapy that precludes safe delivery of thoracic stereotactic radiotherapy (relative contraindication)\n* Patients requiring chest radiotherapy for an active cancer (relative contraindication)\n* VT targets cannot be identified or are not suitable for targeting with stereotactic radiotherapy (such as multiple foci of arrhythmia)\n* Patients who cannot tolerate the radiotherapy treatment position, or whose body habitus is not permissible by treatment bed requirements\n* Pregnant or breast-feeding women\n* Patients being considered for cardiac transplant who are deemed not eligible by their transplant team for STAR",{"count":121,"type":22},20,[123],"NA","Ventricular tachycardia (VT) is a dangerous fast heart rhythm originating from scarred areas of the heart muscle, often after a heart attack or in patients with cardiomyopathy. Patients with VT and structural heart disease typically receive an implantable cardioverter-defibrillator (ICD) to prevent sudden death. Despite the ICD, recurrent VT and ICD shocks remain common and are associated with poor quality of life. Current preventive therapies - antiarrhythmic medications and catheter radiofrequency ablation - have important limitations including side effects, incomplete effectiveness, and procedural risk.\n\nStereotactic Arrhythmia Radioablation (STAR) is a non-invasive treatment in which a single, precisely targeted dose of radiation is delivered to the scar tissue that gives rise to the abnormal heart rhythm. STAR has previously been studied in patients who have failed catheter ablation or are too high risk for that procedure, with promising results. However, STAR has not been formally evaluated as a first-line treatment.\n\nThis single-arm prospective feasibility study will enroll 20 adults with structural heart disease and sustained monomorphic VT. Each participant will receive a single 25 Gy fraction of stereotactic body radiotherapy (VMAT technique) targeted at the arrhythmogenic substrate identified by cardiac imaging, 12-lead ECG, and (where available) non-invasive electrocardiographic mapping or electroanatomical mapping. Participants will be followed at 6 weeks, 3, 6, 9, and 12 months to assess the primary efficacy outcomes (death, appropriate ICD shock, VT storm, and sustained VT below ICD detection rate after a 6-week blanking period) and safety outcomes (acute heart failure decompensation, drop in left ventricular ejection fraction, and STAR-specific toxicities such as pneumonitis, esophagitis, and pericarditis). The hypothesis is that STAR delivered as first-line therapy is safe and effective, with a comparable toxicity and efficacy profile to catheter radiofrequency ablation.",[126,31],"Ventricular Tachycardia, Monomorphic",[128,129,130,131,132],"Stereotactic Body Radiotherapy","Cardiac Radioablation","Radioablation","Implantable Cardioverter Defibrillator","STAR-VT","2026-05-24",{"date":135,"type":44},"2026-06-01",{"date":109,"type":22},{"date":138,"type":22},"2029-07",{"name":140,"class":85},"Southlake Health",{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":149,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":86},"100411735","noninvasive-cardiovascular-diagnosis-of-patients-with-fully-magnetically-levitated-blood-pumps-100411735","NCT04641416","Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps","Pilot Study: Noninvasive Cardiovascular Diagnosis of Patients With Fully Magnetically Levitated Blood Pumps","HM3_Snoopy","Inclusion Criteria:\n\nAll patients with the HeartMate 3 system implanted at the Medical University of Vienna, which are able and willing to understand and sign the informed consent form, and which do not meet any exclusion criteria will be included.\n\nExclusion Criteria:\n\n* Age: \\\u003C18 or \\>75 years\n* Inability to provide informed consent\n* Patients with known intraventricular or aortic root thrombus formation or known pathology of the coagulatory system. Although an intraventricular thrombus formation is usually removed intraoperatively during the LVAD implantation procedure, the rationale for this exclusion criterion is to avoid suction of such thrombus material during possible speed changes (± 20% from the initial pump speed). Consequently, the exclusion of patients with known pathology of the coagulation system, who thus have a higher risk of developing any kind of thrombus formation, is another safety measure.\n* Inaccessibility for transthoracic ultrasound diagnostics. Firstly, as described in the visit and assessment schedule (Appendix), changes in pump speed are only performed under transthoracic echo guidance. Secondly, as described above, echo parameters are required to correlate with the non-invasive CDAS pump data. Therefore, the inaccessibility of ultrasound diagnostics (e.g. due to poor image quality) is another exclusion criterion.",{"count":150,"type":22},60,"Left Ventricular Assist Device (LVAD) therapy has become a well-established treatment option for endstage heart-failure either as a bridge to transplant (BTT) or destination therapy (DT). Monitoring of the pump and with this the cardiac status with the HeartMate 3 (HM3) is currently very limited to infrequent log-files with one data entry every 15 minutes and only limited amount of entries. Due to the low resolution data, the standard HM3 monitoring is not feasible for the evaluation of suction events or in depth analysis of the interaction between LVAD and the remaining native heart function. Aim of this study is to develop noninvasive diagnostics of the cardiac remaining respectively recovering function derived from HeartMate 3 pump data only and compare with standard clinical diagnostic procedures. These procedures include cardiac ultrasound and ECG. After this pilot study, the newly developed methods would allow frequent, simple and automatic monitoring of patients implanted with the HeartMate 3 device. Such continuous assessment of cardiac function would massively help therapy optimization of cardiac protection and, if possible, cardiac recovery.",[153,31,154],"End-stage Heart Failure","Mechanical Circulatory Support",[156,157],"ventricular assist device","non-invasive monitoring","2026-05-05",{"date":160,"type":44},"2026-05-08",{"date":162,"type":44},"2020-07-09",{"date":164,"type":22},"2026-12-30",{"name":166,"class":85},"Thomas Schlöglhofer, PhD, MSc",{"id":168,"slug":169,"hasResults":12,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":17,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100636069","lbbap-vs-cs-pacing-for-crt-in-permanent-atrial-fibrillation-and-heart-failure-sync-af-100636069","NCT07560891","LBBAP vs. CS Pacing for CRT in Permanent Atrial Fibrillation and Heart Failure (SYNC-AF)","Left Bundle Branch Area Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy for Patients With Permanent Atrial Fibrillation and Heart Failure: The SYNC-AF Trial","SYNC-AF","Inclusion Criteria:\n\n1. Age ≥19 years\n2. Indication for CRT (CRT-P or CRT-D) device implantation per current guidelines\n3. Permanent atrial fibrillation (with or without planned AVJ ablation)\n4. Ability to understand the purpose of the study and provide written informed consent\n\nExclusion Criteria:\n\n1. Prosthetic tricuspid valve\n2. Prior myocardial infarction involving the interventricular septal area\n3. Life expectancy less than 12 months\n4. Unable to comply with planned 12-month follow-up for any reason\n5. Pregnancy\n6. History of heart transplantation\n7. Persistent left superior vena cava (PLSVC)","19 Years",{"count":177,"type":22},44,[123],"This is a prospective, multicenter, randomized controlled trial comparing Left Bundle Branch Area Pacing (LBBAP)-based cardiac resynchronization therapy (CRT) with conventional coronary sinus (CS) lead-based CRT in patients with permanent atrial fibrillation (AF) and heart failure (HF) who meet indications for CRT device implantation.\n\nAtrial fibrillation and heart failure frequently coexist, and both rapid heart rate and its irregularity contribute to worsening cardiac function. Atrioventricular junction (AVJ) ablation combined with CRT (biventricular pacing) has been established as an effective strategy for rate control and cardiac resynchronization in this population, supported by Class I recommendation in the 2021 ESC guidelines. However, conventional biventricular CRT via the CS lead can induce artificial electrical dyssynchrony, particularly in patients with a narrow QRS complex, potentially limiting its benefit.\n\nConduction system pacing (CSP), including LBBAP, has emerged as a physiologic alternative that directly stimulates the native conduction system, preserving synchronous ventricular activation. Recent evidence (ALTERNATIVE-AF trial) suggests CSP may be superior to biventricular CRT in permanent AF patients undergoing AVJ ablation. However, no randomized controlled trial has directly compared LBBAP-based CRT with CS lead-based CRT in this specific population.\n\nThe SYNC-AF trial will randomize 44 patients (22 per arm) to either LBBAP or CS pacing for CRT. The primary endpoint is change in left ventricular ejection fraction (LVEF) at 12 months as assessed by echocardiography in a blinded core laboratory. Secondary endpoints include changes in QRS duration, major adverse clinical events, device\u002Fprocedure-related complications, and ventricular arrhythmia burden.",[181,182,31],"Atrial Fibrillation (AF)","Heart Failure",[184,185,186,187,188,189,190,182],"LBBAP","Left Bundle Branch Area Pacing","CRT","Cardiac Resynchronization Therapy","Permanent Atrial Fibrillation","Conduction System Pacing","AVJ Ablation","2026-04-23",{"date":193,"type":44},"2026-05-01",{"date":195,"type":22},"2026-06-30",{"date":197,"type":22},"2029-12-31",{"name":199,"class":85},"Yonsei University",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":93,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":233},"100289553","mayo-avc-registry-and-biobank-100289553","NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",{"count":208,"type":22},1000,"Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[67,31,32,71,211,212,213,214,215,216,217,218,219,220,221,222,223],"Sudden Cardiac Arrest","Sudden Cardiac Death","Arrhythmogenic Right Ventricular Dysplasia","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Sarcoidosis","Cardiac Arrhythmia","Cardiac Sarcoidosis","Myocarditis","Inflammatory Cardiomyopathy","Ventricular Tachycardia","Right Ventricular Outflow Tract Ventricular Tachycardia","2026-04-22",{"date":226,"type":44},"2026-04-27",{"date":228,"type":44},"2018-02-09",{"date":230,"type":22},"2027-03",{"name":232,"class":85},"Mayo Clinic",2,{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":245,"conditions":246,"keywords":248,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100528279","phase-3-cmp-mythic-trial-and-registry---cardiomyopathy-with-myocarditis-therapy-with-colchicine-100528279","NCT06158698","CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine","Single-blinded Randomized Investigator-initiated Controlled Trial to Assess the Efficacy of Colchicine to Treat Patients With Cardiomyopathy With Myocarditis (Chronic Inflammatory Cardiomyopathy)","CMP-MYTHiC","Inclusion Criteria Trial and Registry:\n\n* Males and females with Infl-CMP associated with VA (including high PVC burden), reduced LVEF, or significantly increased levels of natriuretic peptides.\n* Patients of 18 years or older\n* Evidence of myocardial inflammation on CMRI (using 2018 Lake Louis criteria) or FDG-PET performed in the 3 months before randomization to be included in the trial OR in the last 12 months before for the registry.\n* Presence of any of the following characteristics and if symptoms have been present for more than 1 month:\n* Mono-morphic or polymorphic PVC burden of ≥3000 in 24 hours, or NSVTs (defined as \\>3 more consecutive beat lasting \\\u003C30 seconds) or evidence of sustained ventricular tachycardias (SVT).\n* Reduced LVEF on echocardiogram (\\\u003C50%) or on CMRI (\\\u003C60%)-. Increased N-terminal pro-B-type natriuretic peptide (NT- proBNP) concentration of 1000 pg\u002FmL or more, or a B-type natriuretic peptide (BNP) concentration of 200 pg\u002FmL or more\n* Persistence of increased high-sensitivity troponin levels above the upper reference limit (URL) after at least 2 months from the first assessment and at least a mono-morphic or polymorphic PVC burden of ≥1000 in 24 hours.\n\nExclusion Criteria Registry:\n\n* Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,\n* Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)\n* Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry.\n* Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair\u002Freplacement\n* Known chronic infective disease, such as HIV infection or tuberculosis\n* Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer;\n* Any other significant disease or disorder which (expected life expectancy \\\u003C12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.\n\nExclusion Criteria Trial :\n\n* Proven history of myocardial infarction with evidence of ischemic scar on echocardiogram or CMRI,\n* Significant flow-limiting coronary artery disease (stenosis above 50%) on invasive coronary angiography or computed tomography (CT) coronary angiography,\n* Cardiomyopathy attributed to toxins such as alcohol and illicit drugs, or to specific causes (i.e. amyloidosis or hypertrophic cardiomyopathy)\n* Known systemic autoimmune disorder (the exception will be for patients with systemic autoimmune disease or isolated cardiac sarcoidosis with a family history of cardiomyopathy, myocarditis, or arrhythmias, where overlap between an autoimmune event and a genetic background can occur). These patients will undergo genetic tests. Patients with autoimmune systemic disorders and isolated cardiac sarcoidosis with positive genetic tests for MCVG will be included in the registry.\n* Previous history of cardiac surgery for instance correction of congenital heart disease or a valve repair\u002Freplacement\n* Known chronic infective disease, such as HIV infection or tuberculosis\n* Participants involved in another clinical trial, defined by the participation in a clinical trial in which an investigational drug was administered in the 30 days prior to screening, or 5 half-lives of the study drug, whichever is longer;\n* Any other significant disease or disorder which (expected life expectancy \\\u003C12 months), in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial or the participant's ability to participate in the trial.\n* Women with childbearing potential (this exclusion criterion is due to insufficient human information regarding the embryofoetal risk with colchicine)\n* Current symptomatic atrial arrhythmias (including persistent atrial fibrillation) associated with LV dysfunction,\n* Advance heart failure (NYHA III or need for inotropes including levosimendan), or recurrent VA despite previous catheter ablation,\n* Known systemic autoimmune disorder or other conditions at the time of randomization where immunosuppression is assumed useful (i.e. cardiac sarcoidosis),\n* Patients already on chronic immunosuppressive therapies (including colchicine) or in whom immunosuppressive therapy is deemed necessary\n* Contraindication to colchicine, including allergies to this medication and its excipients (i.e., lactose and sucrose),\n* Impaired renal function (eGFR\\\u003C30 ml\u002Fmin\u002F1.73m2),\n* Known history of hepatic cirrhosis or transaminase levels at baseline \\> x3-fold the URL\n* Patients with peripheral eosinophilia (eosinophil count \\>10% of the leukocytes) or known hypereosinophilic syndrome at the time of randomization.\n* Severe gastrointestinal insufficiency (for instance, malabsorption syndrome, severe chronic diarrhea)\n* Women during breastfeeding",{"count":243,"type":22},80,[25],"Two-parallel groups randomized, single-blinded, multi-center phase III controlled trial in patients with chronic inflammatory cardiomyopathy to assess the efficacy of colchicine and associated prospective registry to assess the prognostic value of positive genetic testing in this population.",[31,220,221,182,247],"Ventricular Arrythmia",[249,250,251,252,253,254,255],"treatment","trial","colchicine","registry","inflammation","outcome","genetic testing","2026-04-15",{"date":258,"type":44},"2026-04-20",{"date":260,"type":44},"2023-11-14",{"date":262,"type":22},"2028-05-02",{"name":264,"class":85},"Niguarda Hospital",10,{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":93,"sex":17,"minAge":274,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100507694","ai-powered-ecg-analysis-using-willem-software-in-high-risk-cardiac-patients-willem-100507694","NCT05890716","AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)","Evaluation of Electrocardiographic Data From High-risk Cardiac Patients Using Willem™ Cardiologist-level Artificial Intelligence Software. WILLEM Trial.","WILLEM","Inclusion Criteria:\n\n* Patient presenting relevant cardiac arrhythmias and cardiac patterns (including supraventricular tachycardias, abnormal ECG patterns, ventricular tachycardias, ventricular fibrillation, pulseless electrical activity or asystole among others) that have been recorded with at least one short-term ECG medical device according to guidelines with ≥1 signal-channel.\n* Patient with suspected or diagnosed acute\u002Fchronic cardiac diseases (including patients with heart failure, patients with history of cardiac arrhythmias, patients with probable coronary artery diseases, patients with cardiomyopathies, patients with pacemakers or implantable cardioverter-defibrillators (ICD), patients with indication of pacemaker or ICD in current or short-term phase, patients participating in other interventional clinical investigation, patients with hemodynamic instability or acute coronary syndromes, pregnant patients, patients with cancer and chemotherapy, patients with life-expectancy lower than 24 months, patients with in or out-of-hospital cardiac arrest with ventricular fibrillation as first documented rhythm).\n* At least one ECG tracing that can be exported in raw data.\n* Signed informed consent. Patients unable to consent, it will be requested to an authorized relative.\n\nExclusion Criteria:\n\n* Unwillingness or inability to sign study written informed consent.\n* Unavailable or suboptimal quality of the electrocardiographic signal in raw data.","4 Years",{"count":276,"type":22},5342,"WILLEM is a multi-center, prospective and retrospective cohort study.\n\nThe study will assess the performance of a cloud-based and AI-powered ECG analysis platform, named Willem™, developed to detect arrhythmias and other abnormal cardiac patterns. The main questions it aims to answer are:\n\n1. A new AI-powered ECG analysis platform can automatice the classification and prediction of cardiac arrhythmic episodes at a cardiologist level.\n2. This AI-powered ECG analysis can delay or even avoid harmful therapies and severe cardiac adverse events such as sudden death.\n\nThe prerequisites for inclusion of patients will be the availability of at least one ECG record in raw data, along with patient clinical data and evolution data after more than 1-year follow-up.\n\nCardiac electrical signals from multiple medical devices will be collected by cardiology experts after obtaining the informed consent. Every cardiac electrical signal from every subject will be reviewed by a board-certified cardiologist to label the arrhythmias and patterns recorded in those tracings. In order to obtain tracings of relevant information, \\>95% of the subjects enrolled will have rhythm disorders or abnormal ECG's patterns at the time of enrollment.",[31,279,280,212],"Cardiac Arrest","Cardiac Arrhythmias",[282,283,284,285,286,287],"Artificial intelligence","Cardiac arrhythmias","Heart disease","Cardiac electrical signals","Electrocardiogram","Electrogram","2026-03-30",{"date":290,"type":44},"2026-04-03",{"date":292,"type":44},"2023-04-04",{"date":294,"type":22},"2026-11",{"name":296,"class":51},"Idoven 1903 S.L.",14,{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":304,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":23,"phases":307,"briefSummary":308,"conditions":309,"keywords":313,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":323,"locationsCount":86},"100462485","phase-1-phase-ia-and-ib-study-of-aavrh10hfxn-gene-therapy-for-the-cardiomyopathy-of-friedreichs-ataxia-100462485","NCT05302271","Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia","Inclusion Criteria:\n\n* Males and females, age 12 to 50\n* Willing and able to provide informed consent\n* Definitive diagnosis of FA, based on clinical phenotype and genotype (GAA expansion on both alleles)\n* \\>600 GAA repeats in intron 1 in at least one allele\n* FARS and SARA neurologic scores consistent with diagnosis of Friedreich's ataxia\n* Left ventricle ejection fraction (EF) measured by cardiac MRI of ≥35% to 75%\n* Evidence of FA-related cardiac disease, must meet the following criteria: must be abnormal in ≥2 of the following parameters, at least one of which is an abnormal cardiac MRI left ventricular mass index or abnormal cardiopulmonary exercise test\n\n  1. Adults: In the absence of other factors known to cause left ventricular hypertrophy, cardiac MRI left ventricular mass index \\>2 standard deviations above the normal range (males \\>84 gm\u002Fm2, females \\>69 gm\u002Fm2 or Pediatrics: In the absence of other factors known to cause left ventricular hypertrophy, cardiac MRI left ventricular mass index \\>95th centile based on normal BSA for their age and gender\n  2. Cardiopulmonary arm crank testing with assessment of VO2 max ≤20 mL\u002Fkg-min, peak VO2 ≥10 mL\u002Fkg-min while maintaining revolutions of ≥40\u002Fmin. To insure consistency of effort, peak RER ≥1.0\n  3. Cardiac MRI stroke volume index \\\u003C45 mL\u002Fm2\n  4. Cardiac MRI global longitudinal left ventricular strain \\\u003C20%\n  5. Serum high-sensitivity cardiac troponin above the normal range\n* Fibrosis ≤10% in the left ventricular wall on late gadolinium enhancement cardiac MRI\n* Resting O2 saturation ≥95%\n* Serum neutralizing anti-AAVrh.10 titer \\\u003C1:125\n* Hematocrit \\>30%\n* White blood cell levels within normal limits\n* Normal prothrombin, partial thromboplastin time\n* Normal liver-related serum parameters (ALT, AST, ALP, bilirubin); normal liver ultrasound and serum alpha fetoprotein\n* Normal kidney function as assessed by plasma urea and creatinine; estimated GFR \\>30 mL\u002Fmin\u002F1.73m2\n* No evidence of active infection of any types, including hepatitis virus (A, B or C), human immunodeficiency virus (HIV-1 and HIV-2), or SARS-CoV2\n* Fertile individuals should utilize barrier birth control measures to prevent pregnancy for up to 6 months after vector administration\n* Individuals not receiving experimental medications or participating in another experimental protocol for at least 12 wk prior to entry to the study (individuals who are\u002Fhave received approved therapy will be included).\n* Capable of undergoing cardiac MRI\n* No contraindications to receiving corticosteroid immunosuppression\n\nExclusion Criteria:\n\n* Individuals receiving corticosteroids or other immunosuppressive medications\n* Individuals with uncontrolled diabetes (glycated hemoglobin, HbA1c levels \\>7%)\n* Genotype FA missense mutation on one or both alleles\n* Evidence of infection defined by elevated white blood cell count, temperature \\>38.5̊ C, infiltrate on chest x-ray\n* Decompensated heart failure (NY4A class III-IV at time of baseline clinical assessment)\n* Hemoglobin \\\u003C10 g\u002Fdl\n* Absolute neutrophil count \\\u003C1500 cells\u002Fmm3\n* Platelet count \\\u003C100,000 cells\u002Fmm3\n* Hemodynamically unstable atrial or ventricular arrhythmias which require medical intervention\n* Contraindication to cardiac MRI (e.g., non-MRI compatible pacemaker\u002Fdefibrillator) or gadolinium (known or suspected hypersensitivity, glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m2)\n* Any malignancy during the last five years, except basal cell skin cancer\n* Unrelated clinical condition with life expectancy \\\u003C12 months (prohibiting follow-up)\n* Concomitant conditions (other than FA) known to produce left ventricular hypertrophy, including aortic stenosis, systemic hypertension (BP ≥140\u002F90 on noninvasive blood pressure), or genetically mediated hypertrophic cardiomyopathy\n* Use of oxygen supplementation\n* Risk for thromboembolic disease, including history of thromboembolic disease hospitalization within the last 90 days, recent trauma and\u002For recent surgical procedure. If the history of thromboembolic disease is not definitive, the subject will be excluded if laboratory testing suggests a risk for thromboembolic disease because of mutations in the protein-S, protein C, antithrombin, factor V Leiden or prothrombin gene\n* Any uncontrolled psychiatric disease\n* Pregnant or breastfeeding woman\n* Prior participation in any gene and\u002For cell therapy\n* Known obstructive coronary artery disease (as documented by clinical history of myocardial infarction, prior coronary revascularization or angina symptoms (Canadian Cardiovascular Society grade ≥2 at time of baseline clinical assessment), or epicardial obstructive coronary artery disease (≥ 50% left main, ≥ 70% of other major coronary arteries)\n* Any lung function abnormalities that would affect cardiopulmonary testing\n* Any condition, disorder, or abnormal laboratory test findings at screening which, in the judgment of the investigator, would interfere with the individual's ability to comply with all study requirements, or would require the administration of treatment during the study that could potentially affect the interpretation of the study data, or would place the individual at an unacceptable risk by his\u002Fher participation in the study\n* If prior infection with SARS-CoV2, any related residual cardiac or pulmonary abnormalities\n* Alcoholism or drug addiction (see reference 71 for alcoholism, reference 72 for drug addiction)","12 Years","50 Years",{"count":7,"type":22},[99],"The purpose of this study is to test the safety and preliminary efficacy of AAVrh.10hFXN to treat the cardiomyopathy associated with Friedreich's ataxia (FA). AAVrh.10hFXN is a serotype rh.10 adeno-associated virus gene transfer vector coding for Frataxin (FXN). The drug is administered intravenously. This is a phase 1, open label, dose escalation study with a total of 25 participants.",[310,31,311,312],"Friedreich Ataxia","Cardiac Hypertrophy","Myocardial Fibrosis",[314,315,316,317],"Ataxia","Friedreich's ataxia","Pediatric","Gene therapy",{"date":319,"type":44},"2026-03-31",{"date":321,"type":44},"2022-02-22",{"date":197,"type":22},{"name":324,"class":85},"Weill Medical College of Cornell University",{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":332,"targetDuration":305,"studyType":61,"phases":4,"briefSummary":334,"conditions":335,"keywords":336,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":86},"100409500","the-heart-hive---cardiomyopathy-study-100409500","NCT04612296","The Heart Hive - Cardiomyopathy Study","A Longitudinal Observational Study of Self-reported Cardiomyopathy in the Heart Hive","Inclusion Criteria:\n\n* Adult (age 18 and over),\n* Males and Females,\n* Capacity to provide informed consent,\n* Patients with a confirmed diagnosis of cardiomyopathy or myocarditis,\n* People with a family history of cardiomyopathy confirmed in a first or second degree relative.\n\nNote: Pregnant women are eligible. This study is observational and entirely separate from clinical care.\n\nExclusion criteria:\n\n* Patients who lack capacity to consent for themselves,\n* Vulnerable groups (e.g. those under 18, prisoners, those in a dependent relationship, the mentally ill).\n* Patients with a confirmed history of coronary artery disease:\n* who have been informed by their treating physician that their cardiomyopathy is secondary to their coronary artery disease, or\n* who have undergone previous percutaneous coronary intervention or coronary bypass surgery\n* History of primary valvular heart disease or congenital heart disease\n* Severe, untreated or untreatable hypertension (systolic blood pressures routinely \\>180 mm Hg and\u002For diastolic blood pressures \\>120 mm Hg)",{"count":333,"type":22},10000,"This is an online registry and database of patients with cardiomyopathy and myocarditis, coupled with an observational study of cardiomyopathies.",[31,220],[337,338,339,340,341],"Takotsubo","Dilated cardiomyopathy","hypertrophic cardiomyopathy","ARVC","ACM","2026-03-24",{"date":344,"type":44},"2026-03-27",{"date":346,"type":44},"2019-11-09",{"date":348,"type":22},"2027-09",{"name":350,"class":85},"Imperial College London",{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":375},"100441903","phase-4-the-pivatal-study--study-of-ventricular-arrhythmia-vta-ablation-in-left-ventricular-assist-device-lvad-patients-100441903","NCT05034432","The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients","Prophylactic Intra-Operative Ventricular Arrhythmia Ablation in High-Risk LVAD Candidates (PIVATAL)","PIVATAL","Inclusion Criteria:\n\n* Age \\> 18 years\n* Presence of advanced cardiomyopathy (of all INTERMACS classification) and eligible for LVAD implant per the decision of the Heart Failure clinical team\n* Implanted cardioverter defibrillator (ICD) any time in past with remote monitoring or planned to undergo ICD (or ICM as an alternative, if an ICD cannot be implanted for a clinical reason) implant within the index hospitalization for LVAD implant\n* History of treated or monitored sustained (i.e., \\>30 seconds in duration ) VT or VF episode within the past 5 years.\n\nExclusion Criteria:\n\n* Past successful VTA ablation without recurrent VTA prior to LVAD implant (Patients who continue to experience VTA post ablation and pre LVAD implant qualify to be enrolled)\n* Participation in other clinical trials (observational registries are allowed with approval)\n* Unable or unwilling to provide informed consent",{"count":360,"type":22},100,[362],"PHASE4","To investigate the effect of VTA ablation at the time of LVAD implant to see if it can reduce the incidence of VTA after surgery",[365,31],"Arrythmia","2026-03-19",{"date":368,"type":44},"2026-03-23",{"date":370,"type":44},"2022-05-27",{"date":372,"type":22},"2027-06-30",{"name":374,"class":85},"University of Rochester",19,{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":393,"completionDateStruct":394,"leadSponsor":396,"locationsCount":4},"100630712","rhythm-and-myocardial-function-relationship-evaluation-in-heart-diseases-100630712","NCT07491237","RHYthm and Myocardial Function Relationship Evaluation in Heart Diseases","RHYME-HD","Inclusion Criteria:\n\n* Only patients aged \\> 18 years with a history of arrhythmia warranting non-pharmacological treatment according to the guidelines will be selected.\n* Collection of informed consent for the prospective cohort.\n* For the retrospective cohort, the Promoter has carried out a Data Protection Impact Assessment (DPIA), which ascertained the adequacy of the technical and organisational measures adopted to ensure the protection of the fundamental rights and freedoms of data subjects, in accordance with Article 89 of Regulation (EU) 2016\u002F679 and the guidelines of the Data Protection Authority. Data processing will be limited to the purposes of the study and conducted in accordance with the principles of minimisation, pseudonymisation and security, in compliance with the guarantees defined by the Data Protection Authority.\n\nExclusion Criteria:\n\n* Patients who, upon initial assessment at our centre, do not present arrhythmias that would indicate non-pharmacological treatment.\n* Patients for whom it is not possible to obtain adequate medical history and\u002For follow-up through medical examination or telephone consultation.\n* Refusal to give informed consent to participate in the study.",{"count":384,"type":22},253,"Arrhythmias are widespread among the global population. Although they can occur in healthy hearts, they are often the manifestation of a hereditary or acquired heart muscle disease, and may be the cause or, more often than not, the consequence.\n\nIn recent decades, with advances in medical knowledge and technology, non-pharmacological therapies for arrhythmias have become increasingly popular. These fall into two broad categories: therapies aimed at electrostimulation and those aimed at ablation of arrhythmias.\n\nThe selection of patients eligible for these procedures is essential for the effectiveness of the therapy, the reduction of complications and the optimisation of resources.\n\nNot all patients, even those selected according to guidelines, respond equally to the chosen therapy. Other patients, due to their clinical\u002FECG characteristics, do not have clear indications and remain in a borderline area where the class of evidence and\u002For recommendation of the guidelines is less stringent. Still others develop recurrences or complications during follow-up that require further intervention.\n\nIn this context, it is essential in the study of these patients not only to use standard instrumental examinations, such as echocardiograms, Holter ECGs and stress tests (simple and cardiopulmonary), but also and above all to use advanced imaging methods (STE, 3D echo, MRI, CT, PET-CT) and remote monitoring tools that integrate diagnostic algorithms managed by artificial intelligence.\n\nIn light of these considerations, our project consists of conducting an observational study that includes all patients with arrhythmias who are candidates for electrostimulation and\u002For ablation procedures at the Arrhythmology Unit and\u002For followed up at the Arrhythmology Clinic of our Polyclinic, in order to assess the clinical and\u002For imaging characteristics associated with a worse prognosis in this population, in terms of response to therapy and development of complications. Our main aim is to identify, within the above-mentioned population, the subgroups of responder patients versus non-responder patients, i.e. those with a worse prognosis , who deserve greater attention and more frequent follow-up.",[387,388,389,390,247,182,31],"Arrhythmia","Cardiomyopathy, Dilated","Systolic Dysfunction","Atrial Fibrillation","2026-03-18",{"date":342,"type":44},{"date":256,"type":22},{"date":395,"type":22},"2031-12-31",{"name":397,"class":85},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":4,"eligibilityCriteria":404,"healthyVolunteers":93,"sex":17,"minAge":18,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":408,"conditions":409,"keywords":412,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":425},"100427235","ppg-to-predict-ejection-fraction-and-other-echographic-data-in-the-general-population-100427235","NCT04843371","PPG to Predict Ejection Fraction and Other Echographic Data in the General Population","Photoplethysmography (PPG) to Predict Ejection Fraction and Other Echographic Data in the General Population","Inclusion Criteria:\n\n* Male or Female aged18 years or older.\n* Patients scheduled to undergo an echocardiogram at Tulane Medical Center.\n\nExclusion Criteria:\n\n* Participants under 18 years of age.\n* Participants with cognitive impairments.\n* Participants with a physical inability to wear the Biostrap during the echocardiogram.\n* Individuals who cannot read, speak, and\u002For understand English.","120 Years",{"count":407,"type":22},500,"The investigators are aiming to investigate the association between ejection fraction (EF) determined by echocardiography and signals obtained from Photoplethysmography (PPG) in the general population. The investigators are also aiming to investigate the association between blood pressure and signals obtained from PPG in the general population.\n\nFinally, the investigators are also aiming to investigate the association between signals obtained from PPG in the general population to cardioechographic findings such as, valvular heart disease, structural heart diseases, cardiomyopathies, pericardial disease etc.",[410,411,31],"Valvular Heart Disease","Pericardial Disease",[413,414,415],"Structural heart disease","Photoplethysmography","Ejection Fraction","2026-03-03",{"date":418,"type":44},"2026-03-05",{"date":420,"type":44},"2021-08-20",{"date":422,"type":22},"2026-12",{"name":424,"class":85},"Tulane University",3,{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":304,"maxAge":4,"enrollmentInfo":433,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":435,"conditions":436,"keywords":438,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":425},"100565635","pkp2-acm-natural-history-study-100565635","NCT06644742","PKP2-ACM Natural History Study","The Natural History of Arrhythmogenic Cardiomyopathy With Pathogenic Plakophilin-2 Variants (PKP2-ACM): An Observational Cohort Study","Inclusion Criteria\n\nPatients must meet all the following criteria (and none of the exclusion criteria) to be eligible for study participation:\n\n1. Male or female age 12 years or older at the time of providing informed consent (i.e., ICF provision).\n2. Capable and willing to provide signed informed consent and\u002For assent, which includes compliance with the requirements and restrictions listed in the ICF and protocol.\n3. Clinical diagnosis of arrhythmogenic cardio myopathy (ACM)\n4. Documentation of a pathogenic or likely pathogenic variant in PKP2 by a CLIA-certified genetic testing laboratory\n5. History of ICD implantation ≥6 months prior to ICF provision\n6. Left ventricular ejection fraction by echocardiogram or cardiac magnetic resonance (CMR) ≥50% at ≤12 months prior to ICF provision\n\nExclusion Criteria\n\nPatients meeting any of the following criteria are excluded from study participation:\n\n1. Gene testing indicates that the subject's arrhythmia or cardiomyopathy may be related to a genetic etiology other than PKP2 truncating variant.\n2. Concurrent participation in any other clinical investigation involving use of an investigational agent that could confound results of this study.\n3. Previous participation in a study of gene transfer or gene editing.\n4. NYHA Class IV heart failure.\n5. Presence or requirement for mechanical circulatory support (MCS) or predicted need for MCS or heart transplantation within 6 months of enrollment.\n6. Prior cardiac or other organ (lung, liver, other) transplantation.\n7. Pacemaker dependent rhythm documented, as assessed by the principal investigator ≤12 months prior to enrollment.\n8. Positive human immunodeficiency virus (HIV) antibody test.\n9. Unwillingness to comply with study procedures, including follow-up as specified by this protocol, or unwillingness to fully cooperate with the investigator.",{"count":434,"type":22},36,"The goal of this study is to describe the natural history and clinical events for patients who have Arrhythmogenic Cardiomyopathy with Pathogenic Plakophilin-2 Variants (PKP2-ACM) managed with standard of care.",[31,32,71,437],"Genetic Diseases",[439,440,441,442],"Arrhythmogenic Cardiomyopathy","Plakophilin-2","Arrhythmogenic Cardiomyopathy (AC, ARVD\u002FC)","PKP2","2026-02-24",{"date":445,"type":44},"2026-02-27",{"date":447,"type":22},"2026-03",{"date":449,"type":22},"2031-04",{"name":451,"class":51},"Rocket Pharmaceuticals Inc.",{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":461,"conditions":462,"keywords":464,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":86},"100543828","radiotherapy-vs-catheter-ablation-for-ventricular-tachycardia-in-structural-heart-disease-100543828","NCT06360939","Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease","RadioAblate-VT","Inclusion Criteria:\n\n1. Structural heart disease (including ischaemic cardiomyopathy , non-ischaemic cardiomyopathy or congenital heart disease and defined as any one of\n\n   1. segmental or global decreased ventricular wall motion as defined by TTE, CT or cMRI\n   2. myocardial hypertrophy\n   3. myocardial scar (evidenced by late gadolinium enhancement on cMRI, wall thinning on cardiac CT, low voltage on electrophysiological study or abnormal intracardiac echocardiography)\n2. Recurrent monomorphic VT which can include\n\n   1. at least one episode of VT treated by ICD and\u002For\n   2. sustained VT (lasting \\>30s) and\u002For\n   3. inducible sustained VT on invasive electrophysiological study (EPS) or non-invasive programmed stimulation (NIPS)\n3. PAINESD score of ≥9 points and\u002For at least moderate risk of VT recurrence or death as defined by the I-VT score. Both are validated tools used clinically to identify patient at high risk of VT recurrence and\u002For mortality after CA.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Life expectancy \\\u003C 3 months\n3. Catheter ablation deemed futile or with prohibitive risk by cardiac electrophysiologist.\n4. Unwilling or unable to provide consent\n5. Known cardiac channelopathies (e.g. Catecholaminergic polymorphic ventricular tachycardia (CPVT), long- or short QT syndrome, Brugada syndrome)\n6. Contraindications to radiotherapy as deemed by referring physician and\u002For radiation oncologist\n7. Pregnancy or breast feeding",{"count":150,"type":22},[123],"The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are:\n\n* What is the efficacy of SBRT compared to catheter ablation (CA) in achieving a ≥ 75% reduction in VT burden at 6 months\n* What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care).",[222,31,463,247],"Arrhythmias, Cardiac",[465,466,467,468],"catheter ablation","stereotactic body radiation therapy","non invasive","radioablation","2026-02-15",{"date":471,"type":44},"2026-02-18",{"date":473,"type":44},"2025-11-03",{"date":475,"type":22},"2027-12-20",{"name":477,"class":85},"Western Sydney Local Health District",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":486,"maxAge":487,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":491,"conditions":492,"keywords":495,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":513},"100522242","phase-2-multicenter-trial-of-ecmo-in-children-with-severe-cardiac-failure-using-the-cardiohelp-system-100522242","NCT06080074","Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System","Multicenter Trial to Evaluate the Safety and Effectiveness of the Cardiohelp System for up to 30 Days of Support in Children With Severe Cardiac Failure","TROLLEY","Inclusion Criteria:\n\n1. Age 0 to 16 years of age (i.e., \\\u003C17 years)\n2. Body weight 3 to 80 kilograms\n3. VA-ECMO use for primary cardiac failure using the Cardiohelp system.\n4. First ECMO run during the current hospitalization\n\nExclusion Criteria:Children must not meet any of the following exclusion criteria within 48 hours prior to device implant:\n\n1. Gestationally-corrected age \\\u003C37 weeks\n2. Bleeding or coagulopathy that is a contraindication to anticoagulation\n3. Irreversible renal, hepatic or lung failure\n4. Stroke or uncertain neurological status within the past 30 days\n5. Severely malnourished\n6. Use of an ECMO system other than the Cardiohelp\n7. VV-ECMO or ECMO for primary respiratory failure\n8. Goals of patient to focus on comfort measures only.\n9. Failure to separate from cardiopulmonary bypass\n10. Allergy or contraindication to receiving UFH or bivalirudin as a primary anticoagulant on ECMO.\n11. Patients who are pregnant or breastfeeding.\n12. Unable to undergo randomization within 30 hours following ECMO cannulation (randomized cohort only)","0 Years","16 Years",{"count":5,"type":22},[490],"PHASE2","There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to:\n\n1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of support in children with severe heart failure with the goal to support its FDA clearance in children.\n2. To evaluate heparin versus bivalirudin as the primary blood thinner (anticoagulant) in a randomized trial of children supported with the Cardiohelp ECMO System with the goal to plan a phase III (pivotal) randomized clinical trial\n\nThe main questions the Cardiohelp single-arm trial seeks to answer are:\n\n* What is the safety and effectiveness of the Cardiohelp device for pediatric ECMO?\n* Should the Cardiohelp device be FDA-cleared for children based on the results of the study?\n* What are the optimal performance specifications of the Cardiohelp device in children?\n\nThe main questions the blood thinner randomized trial seeks to answer are:\n\n* Which blood thinner is more promising (i.e., more effective and safer) in children on the Cardiohelp device?\n* How should a pivotal trial of heparin vs. bivalirudin be designed so it is the most informative and efficient to determine the best blood thinner?\n\nChildren who are receiving the Cardiohelp device will be approached and consented to participate if interested. For the Cardiohelp device trial, participants will undergo a standardized data collection to estimate survival to 30 days and the prevalence of serious adverse events like stroke, bleeding, and hemolysis. For the blood thinner randomized trial, participants will be randomized 1:1 to blood thinner strategy to determine which blood thinner has the fewest bleeding and clotting complications.\n\nFor the Cardiohelp single-arm trial, participant outcomes will be compared to performance goals (PG) derived from the ECMO literature. For the blood thinner randomized trial, the amount of bleeding and clotting will be measured.\n\nThe study is funded by an R01 grant from the FDA's Office of Orphan Product Development (OOPD).",[182,493,494,31],"Cardiogenic Shock","Congenital Heart Disease",[496,497,498,499,500,501,502,503],"blood thinner","ECMO","heart failure","bivalirudin","heparin","FDA regulation","pediatric medical devices","510k clearance","2026-01-27",{"date":506,"type":44},"2026-01-29",{"date":508,"type":44},"2025-04-15",{"date":510,"type":22},"2029-09",{"name":512,"class":85},"Stanford University",5,{"id":515,"slug":516,"hasResults":12,"nctId":517,"briefTitle":518,"officialTitle":518,"acronym":4,"eligibilityCriteria":519,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":522,"conditions":523,"keywords":530,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":86},"100620597","multimodal-analysis-of-endomyocardial-biopsies-100620597","NCT07359690","Multimodal Analysis of Endomyocardial Biopsies","Inclusion Criteria:\n\n* Patients aged \\>18 years with a clinical indication for endomyocardial biopsy.\n* Patients capable of providing informed consent who have signed the consent form for participation in the study.\n\nExclusion Criteria:\n\n* Patients without a clinical indication for endomyocardial biopsy (EMB).\n* Pregnant individuals.\n* Patients incapable of providing informed consent.\n* Women of childbearing potential who are not using adequate contraception.",{"count":521,"type":22},216,"The goal of this observational study is to pursue a multimodal approach to identify the molecular signatures and immune signalling molecules of various myocardial diseases and thereby contribute to improving diagnosis and therapy.\n\nThe main aim is:\n\n-Identification of molecular profiles (e.g., proteome, lipidome, metabolome) and immune signalling profiles that are specifically associated with different myocardial diseases and the post-heart transplantation course.\n\nParticipants already receiving an endomyocardial biopsy as part of their regular medical care will be enrolled. An additional biopsy sample will be taken for the above mentioned research.",[524,525,526,527,528,31,529],"Heart Transplantation","Dilated Cardiomyopathy (DCM)","Hypertrophic Cardiomyopathy (HCM)","Myocarditis, Pericarditis","Amyloidosis Cardiac","Sarcoidosis of the Heart",[531,532],"Endomyocardial biopsy","Multimodal analysis","2026-01-15",{"date":535,"type":44},"2026-01-22",{"date":537,"type":44},"2025-10-27",{"date":539,"type":22},"2028-09-30",{"name":541,"class":85},"University Hospital, Essen",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":550,"enrollmentInfo":551,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":553,"conditions":554,"keywords":557,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":571},"100112813","prospective-observational-study-of-the-icd-in-sudden-cardiac-death-prevention-100112813","NCT00733590","Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention","Prospective Observational Study of the ICD in Sudden Cardiac Death Prevention (PROSe-ICD)","PROSe-ICD","Inclusion Criteria:\n\n* History of acute MI at least 4 weeks old\n* Non-ischemic LV dysfunction for at least 9 months\n* Who have an ejection fraction (EF) \\\u003C or = to 35%\n* Undergone elective replacement indicator (ERI) generator replacement of an FDA-approved ICD for primary prevention of SCD within 24 months of enrollment.\n* Who have primary prevention implants.\n\nExclusion Criteria:\n\n* ICD generator replacement for secondary prevention\n* Inability or unwillingness to provide valid informed consent\n* New York Heart Association Class IV heart failure\n* Patients with pre-existing Class 1 indications for pacemaker therapy.","85 Years",{"count":552,"type":22},1500,"The overall hypothesis of this study is that subtle interactions between structural (substrate) and functional (trigger) abnormalities of the heart, some of which are genetically-determined, can be used to identify patients at high risk of sudden cardiac death (SCD). Such information may be used to better define patients most likely to benefit from replacement of an internal defibrillator (ICD). The prospective, observational study to enroll, categorize and follow patients who receive an ICD pulse generator replacement for primary prevention of SCD (PROSe-ICD) was established to :\n\n1. to gain a better understanding of the biological mechanisms that predispose to SCD\n2. to develop readily determined clinical, electrocardiographic, genetic and blood protein markers identify patients with an increased risk of dying suddenly",[555,556,387,31],"Heart Failure, Congestive","Death, Sudden, Cardiac",[558,559,560,561,562],"defibrillator, implanted","genomics","electrocardiography","electrophysiological study","proteomics",{"date":564,"type":44},"2026-01-20",{"date":566,"type":44},"2003-06",{"date":568,"type":22},"2029-03",{"name":570,"class":85},"Johns Hopkins University",4,{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":579,"enrollmentInfo":580,"targetDuration":4,"studyType":23,"phases":582,"briefSummary":583,"conditions":584,"keywords":587,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":86},"100477030","high-intensity-his-bundle-pacing-in-heart-failure-patients-with-narrow-qrs-outcome-study-100477030","NCT05491655","High Intensity His Bundle Pacing in Heart Failure Patients With Narrow QRS Outcome Study","HIPPOS","Inclusion Criteria:\n\n* Aged 18 or above\n* Ventricular Ejection Fraction (EF) \\\u003C 50%; BNP needs to be ≥250ng\u002FL or N Terminal-pro BNP≥600ng\u002FL for patients with EF 36-50% and they should have an ICD indication\n* New York Heart Association (NYHA) class I-IV\n* Narrow QRS duration (≤110ms) on 12 lead ECG\n\nExclusion Criteria:\n\n* Other serious medical condition with life expectancy of less than 1 year\n* Lack of capacity to consent\n* Pregnancy\n* Previous aortic valve surgery","90 Years",{"count":581,"type":22},34,[123],"Cardiac Resynchronization Therapy (CRT) decreases heart failure hospitalizations and mortality and increases left ventricular Ejection Fraction (EF) in patients with dilated cardiomyopathy, left bundle branch block and QRS duration \\>130msec. His bundle pacing has a similar effect in this category of patients. However, CRT is not beneficial in heart failure (HF) patients with narrow QRS. His-bundle pacing delivers physiological ventricular activation and has been shown to improve acute hemodynamic function in patients with heart failure, a prolonged PR interval, and either a narrow QRS or RBBB through AV delay optimization. We observed an acute hemodynamic effect during application of higher pacing output (3.5 Volts\u002F1 msec) in HF patients with dilated or ischemic cardiomyopathy and narrow QRS independently of the paced QRS duration or AV delay shortening.\n\nThis is a single-center, prospective randomized single-blinded study, recruiting a sub-population of patients with heart failure (dilated or ischemic cardiomyopathy, EF\\\u003C50%, narrow QRS (\\\u003C110 msec), in optimal medical treatment who have an indication for ICD.",[585,586,182,31],"Cardiac Conduction System","His Bundle Pacing",[588,589,75,590,591,415],"His bundle pacing","conduction system pacing","Cardiomyopathy","narrow QRS","2025-12-15",{"date":594,"type":44},"2025-12-22",{"date":596,"type":44},"2023-03-29",{"date":598,"type":22},"2026-05",{"name":600,"class":85},"Miulli General Hospital",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":608,"conditions":609,"keywords":616,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":628,"leadSponsor":630,"locationsCount":86},"100468249","patient-similarity-for-decision-making-in-prevention-of-cardiovascular-toxicity-pact-a-feasibility-study-100468249","NCT05377320","PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study","Inclusion Criteria:\n\n1. Patients ≥18 years with a history of cancer.\n2. Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.\n3. Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.\n4. Ability to understand a written informed consent form, and willing to sign it prior to study registration.\n\nExclusion Criteria:\n\n1. Patient \\\u003C18 years.\n2. Without a personal history of cancer.\n3. Existing cardiomyopathy diagnosed after cancer diagnosis.\n4. Documented cognitive impairment.\n5. Patient or patient representative who is unable and unwilling to sign the informed consent form.",{"count":150,"type":22},"This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.",[182,610,611,612,613,614,31,615],"Coronary Artery Disease","Peripheral Artery Disease","Ischemia","Hypertension","Diabetes Mellitus","Cardiotoxicity",[617,618,619,620,621,622,623],"clinical decision aid","cancer","cardiac dysfunction","cardio-oncology","artificial intelligence","machine learning","adverse events","2025-10-09",{"date":626,"type":44},"2025-10-14",{"date":422,"type":22},{"date":629,"type":22},"2028-12",{"name":631,"class":85},"Medical College of Wisconsin",{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":4,"eligibilityCriteria":638,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":639,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":641,"conditions":642,"keywords":647,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":655,"lastUpdatePostDateStruct":656,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":86},"100272335","genetic-markers-of-cardiovascular-disease-in-epilepsy-100272335","NCT02824822","Genetic Markers of Cardiovascular Disease in Epilepsy","Genetic Markers of Cardiovascular Diseases and the Potential Role in Sudden Unexpected Death in Epilepsy.","Inclusion Criteria:\n\n* Adults ages 18 - 50 with a diagnosis of epilepsy or seizures, or syncope or drowning or cardiac arrest or sudden death or an abnormal ECG suggestive of an arrhythmia\n* Blood-relatives (Aged 18+) of a patient with a history of epilepsy, seizure, cardiac arrest, sudden death, drowning, syncope or arrhythmia\n\nExclusion Criteria:\n\n* Those who are unable to provide written consent.\n* Prisoners (vulnerable population)\n* Seizures secondary to ischemic events\n* Traumatic brain injury resulting in seizures\n* History of cranial surgery\n* History of brain tumor",{"count":640,"type":22},600,"Epilepsy is a common condition which affects over 3 million people in the US. Patients with uncontrolled epilepsy have a lifetime risk of sudden unexpected death (SUDEP) of 35%, which is greatest in those under 40 years of age. The exact mechanisms and causes are not understood but can be due to underlying conditions which affect the heart and brain, which may lead to dangerous heart rhythms and death. Some of these conditions which affect heart and brain have an identifiable genetic cause. This study aims to identify known genetic causes of heart rhythm and sudden death related disorders in patients with epilepsy.",[643,644,645,646,31],"Epilepsy","Seizures","Syncope","Channelopathy",[648,649,211,212,650,651,652,653,654],"Sudden Unexpected Death in Epilepsy","SUDEP","Sleep","Ion channel disease","Long QT syndrome","Brugada","Catecholaminergic Polymorphic Ventricular Tachycardia","2025-09-04",{"date":657,"type":44},"2025-09-08",{"date":659,"type":4},"2016-05",{"date":661,"type":22},"2031-12",{"name":232,"class":85},{"id":664,"slug":665,"hasResults":12,"nctId":666,"briefTitle":667,"officialTitle":668,"acronym":4,"eligibilityCriteria":669,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":670,"targetDuration":4,"studyType":23,"phases":672,"briefSummary":673,"conditions":674,"keywords":681,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":683,"lastUpdatePostDateStruct":684,"startDateStruct":686,"completionDateStruct":688,"leadSponsor":690,"locationsCount":4},"100601897","phase-3-to-evaluate-the-long-term-safety-and-tolerability-of-acoramidis-in-participants-with-newly-diagnosed-attr-cm-act-early-ole-100601897","NCT07116473","To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)","A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients With Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)","Key Inclusion Criteria:\n\nParticipants must have completed the AG10-501 study (ACT-EARLY study) within the past 60 calendar days with a diagnosis of ATTR-CM (based on the AG10-501 protocol definition of ATTR-CM).\n\nKey Exclusion Criteria:\n\n1. Participants who completed the AG10-501 study with a diagnosis of ATTR-PN only, or who permanently discontinued study drug prior to diagnosis of ATTR-CM in AG10-501.\n2. History of AL or another non-TTR amyloid subtype (eg, ApoA-1, gelsolin).\n3. History of a monoclonal paraprotein or abnormal light chains in serum or urine (i.e., MGUS) in which AL has not been ruled out.\n4. Stage IV or V chronic kidney disease (corresponding to an eGFR ≤ 29 mL\u002Fmin\u002F1.73 m2), or undergoing renal dialysis, or recipient of a kidney transplant.\n5. Active malignancy, except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix that has been successfully treated. In the event a participant developed a low-grade and treatable malignancy in the AG10-501 study (eg, low-grade, localized prostate cancer) and the decision by the Investigator at that time was to continue the participant in the AG10-501 study, that participant may still qualify for Study AG10-504 after documentation with the Medical Monitor.\n6. History of any organ transplant (with the exception of corneal transplant).\n7. Known hypersensitivity to acoramidis or any of the excipients within the study drug.\n8. Treatment for ATTR-CM with any ATTR-oriented on- or off-label or OTC product.",{"count":671,"type":22},250,[25],"The AG10-504 study is an open-label extension study of acoramidis in participants with newly diagnosed transthyretin amyloid cardiomyopathy (ATTR-CM) or both ATTR-CM and transthyretin amyloid polyneuropathy (ATTR-PN).",[675,676,29,677,678,679,31,680,33,28],"Amyloidosis in Transthyretin (TTR)","Amyloidosis, Familial","Amyloid Cardiomyopathy, Transthyretin-Related","Amyloidogenic Transthyretin (ATTR) Amyloidosis","Heart Disease","Amyloidosis, Hereditary, Transthyretin-Related",[35,36,28,37,38,39,682],"Hereditary","2025-08-07",{"date":685,"type":44},"2025-08-11",{"date":687,"type":22},"2025-11",{"date":689,"type":22},"2037-12",{"name":50,"class":51},{"id":692,"slug":693,"hasResults":12,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":4,"eligibilityCriteria":697,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":698,"enrollmentInfo":699,"targetDuration":4,"studyType":23,"phases":700,"briefSummary":701,"conditions":702,"keywords":709,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":714,"lastUpdatePostDateStruct":715,"startDateStruct":717,"completionDateStruct":719,"leadSponsor":721,"locationsCount":86},"100602108","the-ipeer2peer-mentorship-program-for-young-adults-with-heart-disease-100602108","NCT07119216","The iPeer2Peer Mentorship Program for Young Adults With Heart Disease","The iPeer2Peer Support Mentorship Program for Young Adult Patients With Heart Disease: A Feasibility Study","Inclusion Criteria:\n\n* Peer Mentor inclusion criteria: (a) heart disease patients, (b) at least three months post-diagnosis, (c) between the ages of 26-35 years old, (d) nominated by a member of their healthcare team as a good candidate to act in the mentor role based on maturity and emotional stability (e.g., good communication skills, positive adaptation and adjustment, strong support network), (e) willingness to commit to virtual peer mentor training, (f) able to speak and read English, and (g) access to a device (e.g., smart phone, tablet, computer) capable of using free WhatsApp software.\n* Peer Mentee inclusion criteria: (a) heart disease patients, (b) between the ages of 18-25 years old, (c) able to speak and read English, and (d) access to a device (e.g., smart phone, tablet, computer) capable of using free WhatsApp software.\n\nHeart disease patients include:\n\n* Patients with any past or present heart failure\n* Patients with cardiomyopathy seen at least 2 times a year\n* Patients who have undergone a Fontan procedure\n* Patients who have undergone a heart transplant\n\nExclusion Criteria:\n\n* Mentor and mentee exclusion criteria include: (a) Significant cognitive impairments as assessed by a qualified healthcare provider (HCP), (b) have a diagnosis of an active psychological disorder (e.g.: Major Depressive Disorder, etc.; determined through chart review by a qualified HCP) likely to influence assessment of health-related quality of life and\u002For interfere with their ability to manage their heart disease care regimen, and (c) are participating in other peer support or self-management interventions.","35 Years",{"count":243,"type":22},[123],"Young adults with heart failure, including those who have undergone a heart transplant, experience considerable psychosocial stressors associated with living with a chronic illness, including heightened levels of anxiety and depression, and poor health-related quality of life compared to 'healthy' peers. Psychosocial challenges during young adulthood are especially concerning as this life stage represents a unique transitional period for fostering self-identity, friendships, mastery, and decision-making competencies. As young people with heart failure transition into adult healthcare systems, they take on greater personal responsibility due to their increasing independence and involvement in care decisions, and require more support and resources to live longer, healthier lives. Peer support provided by a person with a similar experience has been found to improve disease self-management and psychosocial health outcomes in pediatric healthcare.\n\nAn established, online mentorship program, iPeer2Peer (iP2P), will be employed through a pilot feasibility waitlist randomized controlled trial with repeated measures across five sites. Sixty mentees will be recruited and randomized into intervention and control groups. Thirty mentees in the intervention group will be matched 1:1 with 20 trained mentors. These pairings will connect over 12 weeks through video calls and text messaging to provide peer support to improve self-management and psychosocial health outcomes.",[182,703,704,705,706,31,707,708],"Mentorship","Peer Support","Peer Support and Chronic Disease","Young Adults","Heart Transplant Recipient","Fontan Procedure",[498,710,711,712,713],"mentorship","peer support","young adult","heart disease","2025-08-05",{"date":716,"type":44},"2025-08-13",{"date":718,"type":22},"2025-09",{"date":720,"type":22},"2027-12",{"name":722,"class":85},"Samantha Anthony",{"id":724,"slug":725,"hasResults":12,"nctId":726,"briefTitle":727,"officialTitle":727,"acronym":728,"eligibilityCriteria":729,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":730,"enrollmentInfo":731,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":732,"conditions":733,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":714,"lastUpdatePostDateStruct":735,"startDateStruct":737,"completionDateStruct":739,"leadSponsor":741,"locationsCount":86},"100505994","non-invasive-method-for-evaluation-of-cardiac-resynchronization-therapy-100505994","NCT05868616","Non-Invasive Method for Evaluation of Cardiac Resynchronization Therapy","NIME-CRT","Inclusion Criteria:\n\n* Patients referred for CRT implantation or postoperative control at Oslo University Hospital based on the European Society of Cardiology (ESC) guidelines (2021), and criteria below:\n\n  1. Sinus rhythm.\n  2. New York Heart Association class II \u002F III heart failure on diagnosis and on optimal medical therapy.\n  3. Left bundle branch block.\n  4. QRS duration ≥ 130 ms.\n  5. Left ventricular ejection fraction ≤ 40%.\n  6. Patients must have echocardiography examination before implantation\n  7. Informed consent obtained from the patient.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years and \\> 80 years;\n2. Ongoing atrial fibrillation;\n3. Complete atrioventricular block","80 Years",{"count":243,"type":22},"Left bundle branch block (LBBB) exists in about 25% of patients with congestive heart failure and is associated with worsened prognosis. Cardiac resynchronization therapy (CRT) has been one of the most important advancements in the past two decades for patients with LBBB heart failure. However, 30-40% of patients receiving a CRT do not benefit from it. In this study, the investigators will test a noninvasive device to evaluate acute effect of CRT during implantation and at follow-up CRT controls. In addition, echocardiography will be performed during CRT turned ON and OFF to visualize the changes in intraventricular flow and functional parameters of the heart.",[182,734,31,32,71],"Pacemaker DDD",{"date":736,"type":44},"2025-08-06",{"date":738,"type":44},"2023-03-21",{"date":740,"type":22},"2031-03",{"name":742,"class":85},"Oslo University Hospital"]